With the business potentially at an important milestone, we thought we'd take a closer look at MustGrow Biologics Corp.'s (CVE:MGRO) future prospects. MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants. The CA$26m market-cap company posted a loss in its most recent financial year of CA$7.3m and a latest trailing-twelve-month loss of CA$5.4m shrinking the gap between loss and breakeven. As path to profitability is the topic on MustGrow Biologics' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

MustGrow Biologics is bordering on breakeven, according to some Canadian Chemicals analysts. They expect the company to post a final loss in 2027, before turning a profit of CA$8.1m in 2028. Therefore, the company is expected to breakeven roughly 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 106% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving MustGrow Biologics' growth isn’t the focus of this broad overview, but, keep in mind that generally a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for MustGrow Biologics

One thing we’d like to point out is that The company has managed its capital judiciously, with debt making up 10% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on MustGrow Biologics, so if you are interested in understanding the company at a deeper level, take a look at MustGrow Biologics' company page on Simply Wall St. We've also put together a list of key aspects you should further research:

1. Valuation: What is MustGrow Biologics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether MustGrow Biologics is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on MustGrow Biologics’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.